Peripheral Neuropathy: Epidemiology, Pathophysiology and Management | ||
| Zagazig University Medical Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 20 March 2024 | ||
| Document Type: Review Articles | ||
| DOI: 10.21608/zumj.2024.276081.3241 | ||
| Authors | ||
| Sara Ragab Ibrahim Abdel-Fatah* 1; Hadeel A. Elsherbini1; Sherein F. El-sayed2; Randa Salah Gomaa3 | ||
| 1Physiology Department, Faculty of Medicine, Zagazig University | ||
| 2Physiology department, Faculty of Medicine, Zagazig University | ||
| 3physiology,faculty of medicine,zagazig university,zagazig,Egypt | ||
| Abstract | ||
| The term "peripheral neuropathy" refers to a group of illnesses with various causes. Diabetes, immune-mediated diseases, gene mutations, and exposure to harmful drugs including alcohol and chemotherapy are the most frequent causes. To find curable reasons, a complete workup involving a clinical history and physical, nerve conduction studies, and extensive laboratory testing is necessary. It is frequently not clear how to improve glycaemic control specifically in type-2 diabetes, and diabetic peripheral neuropathy is often not well managed. Investigating the workings and efficacy of current treatments is essential. Major worldwide clinical recommendations suggest a number of symptomatic therapies for the therapy of DPN. Tricyclic antidepressants, serotonin–noradrenaline reuptake inhibitors, and calcium channel-blocking anticonvulsants are examples of first-line treatments. Opioids and topical medications like lidocaine and capsaicin are examples of further therapy. Reviewing the epidemiology, pathophysiology, and current guidelines for the pharmacological management of diabetic peripheral neuropathy (DPN) as well as discussing studies pertinent to the ongoing development of pharmacological recommendations for the treatment of DPN are the goals of this work. | ||
| Keywords | ||
| Peripheral Neuropathy; neuropathic pain; opioids | ||
|
Statistics Article View: 162 |
||
